Boston Scientific is pulling its latest transcatheter aortic heart valve platform from the worldwide market and said it will ...

Months after causing safety concerns that led the FDA to hit a related trial with a clinical hold, a phase 2 trial of ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

Merck KGaA has shown off data that fueled its $85 million bet on a late-phase treatment for a rare, locally aggressive tumor.

Teos Therapeutics is throwing in the towel. | iTeos Therapeutics is throwing in the towel. Two weeks after axing its ...

An international group of gene editing leaders has put out a call for a 10-year ban on heritable human genome editing (HHGE), ...

AbbVie is looking south to boost its community-based clinical trials. | AbbVie is looking south to boost its community-based clinical trials. The Chicago-area pharma giant is partnering with Nashville ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. | Eli Lilly is expanding its efforts to ...

Five people have been charged for allegedly participating in an insider trading scheme tied to Novartis’ $3.2 billion ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build ...

Boundless Bio is in a bind. A phase 1/2 trial has revealed the shortcomings of Boundless’ lead candidate, prompting the ...

It’s GlycoEra’s time to shine. The biotech has closed a series B fundraise clocking in at $130 million, with the funds set to ...